# Embecta (EMBC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/EMBC
## Company Profile
- Ticker: EMBC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 5.88 USD
- Market cap: 207053592.73000002 USD
- Last updated: 2026-10-05
## Business Overview
### Global Diabetes Care
Embecta is a global diabetes-care company built on a nearly century-long history in insulin delivery. Its products are used by people who self-administer injectable therapies and by healthcare systems supporting diabetes management.
### Injection-Device Portfolio
The company's core portfolio includes pen needles and syringes, with market-specific products moving through U.S. and European regulatory review. These high-volume consumables serve both branded diabetes therapies and a growing market for injectable GLP-1 medicines.
### Owen Mumford Expansion
The acquisition of Owen Mumford broadens Embecta's drug-delivery capabilities and product range. The company also works with pharmaceutical partners to co-package its pen needles with generic GLP-1 therapies in multiple international markets.
## Why The Stock Is Moving

As of Oct 5, 2026, EMBC closed up 4.07% at $5.88. No new same-company headline was identified in the current news window.

## Future Catalysts

- Regulatory outcomes for market-appropriate pen needles under review by the FDA and for CE Mark certification.
- Market-appropriate syringe launches in selected geographies in the coming months.
- U.S. launch of a GLP-1 small-pack format in the fourth quarter of fiscal 2026.

## Recent News
- 2026-08-31 21:00 EST — [embecta to Participate in Investor Events](https://biopharmsignal.com/news/EMBC/embecta-to-participate-in-investor-events-0d282c24) — Source: Embecta
- 2026-08-07 10:30 EST — [Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results](https://biopharmsignal.com/news/EMBC/embecta-corp-reports-third-quarter-fiscal-2026-financial-results-99a5ad0e) — Source: Embecta
- 2026-08-07 10:00 EST — [embecta Announces Quarterly Cash Dividend](https://biopharmsignal.com/news/EMBC/embecta-announces-quarterly-cash-dividend-971e0322) — Source: Embecta
- 2026-07-23 21:00 EST — [embecta to Report Fiscal Third Quarter Financial Results](https://biopharmsignal.com/news/EMBC/embecta-to-report-fiscal-third-quarter-financial-results-7cbbc9ad) — Source: Embecta
- 2026-06-16 10:30 EST — [embecta appoints Nimish Muzumdar as SVP and President, North America](https://biopharmsignal.com/news/EMBC/embecta-appoints-nimish-muzumdar-as-svp-and-president-north-america-07ce387f) — Source: Embecta